Asylia Diagnostics
Asylia Diagnostics, founded in 2019, is a precision medicine platform focused on immunotherapies. They collect multi-modal data, including molecular, chemical, and real-world evidence (RWE) from patients treated with investigational and standard of care therapies, as well as custom cancer cell lines. Their proprietary generative AI platform, AsyliaAI™, is used to identify patient subgroups, discover biomarkers, and novel drug targets, ultimately de-risking theranostic development. Their technology allows for patient stratification and indication expansion strategies, with a current focus on a molecular test for metastatic melanoma patients treated with immune checkpoint inhibitors (PD-1) to predict adverse events and treatment response. They have filed two PCTs and are building a patent portfolio around theranostics. Traction includes pilot projects with pharma, co-development with IVD partners, and clinical trials in European hospitals. Their business model is focused on providing data science technology and developing diagnostics products for biopharma and IVD partners.
Asylia Diagnostics
Asylia Diagnostics, founded in 2019, is a precision medicine platform focused on immunotherapies. They collect multi-modal data, including molecular, chemical, and real-world evidence (RWE) from patients treated with investigational and standard of care therapies, as well as custom cancer cell lines. Their proprietary generative AI platform, AsyliaAI™, is used to identify patient subgroups, discover biomarkers, and novel drug targets, ultimately de-risking theranostic development. Their technology allows for patient stratification and indication expansion strategies, with a current focus on a molecular test for metastatic melanoma patients treated with immune checkpoint inhibitors (PD-1) to predict adverse events and treatment response. They have filed two PCTs and are building a patent portfolio around theranostics. Traction includes pilot projects with pharma, co-development with IVD partners, and clinical trials in European hospitals. Their business model is focused on providing data science technology and developing diagnostics products for biopharma and IVD partners.